Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Azatiq

(Iberdomide)

Phase 3Small molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Iberdomide is used to treat multiple myeloma, a type of blood cancer, often in combination with other medications. It works by helping the immune system fight cancer cells and preventing the cancer from growing.[1] Azatiq is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]

Azatiq is one of 100 small molecule programs targeting Recurrent Multiple Myeloma. It is currently in Phase 3.

9

Indications

37

Total Trials

30

Active Trials

99

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Recurrent Multiple MyelomaSuspended

Newly Diagnosed Multiple MyelomaRecruiting

Smouldering MyelomaRecruiting

Recurrent GanglioneuroblastomaNot yet recruiting

Multiple MyelomaActive, not recruiting

Non-Hodgkin LymphomaActive, not recruiting

DexamethasoneRecruiting

MRDActive, not recruiting

Newly Diagnosed PatientsNot yet recruiting

Recurrent Multiple MyelomaPhase 1

Suspended

Newly Diagnosed Multiple MyelomaPhase 3

Recruiting

Smouldering MyelomaPhase 2

Recruiting

Recurrent GanglioneuroblastomaPreclinical

Not yet recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Non-Hodgkin LymphomaPhase 1

Active, not recruiting

DexamethasonePhase 2

Recruiting

MRDPhase 2

Active, not recruiting

Newly Diagnosed PatientsPhase 2

Not yet recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Fludara

Ninlaro

Xpovio

KKaryopharm Therapeutics Inc

Opdivo

Bristol-Myers Squibb

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Elranatamab

Vepesid

Mozobil

GGenzyme, a Sanofi Company

BLENREP

GGlaxo Dba Glaxosmithkline

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

MRD

NCT05434689

Phase 1Active, not recruiting

Multiple Myeloma

NCT05560399

Phase 1Recruiting

Recurrent Multiple Myeloma

NCT06465316

Q4 2027

Phase 2Active, not recruiting

Multiple Myeloma

NCT04564703

Q2 2028

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT05392946

Q3 2028

PreclinicalRecruiting

Multiple Myeloma

NCT05583617

Clinical

Trials by Indication[1]

Multiple Myeloma23 trials

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·—·Phase 2·NCT05896228·30 enrolled

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT05560399·7 enrolled

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Active, not recruiting·NNantes University Hospital·Phase 2·NCT04998786·75 enrolled

Show 20 more trials

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04975997·864 enrolled

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Terminated·IiTeos Therapeutics·Phase 1·NCT05289492·16 enrolled

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Active, not recruiting·UUniversity of Nebraska·Phase 2·NCT05177536·40 enrolled

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05354557·16 enrolled

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Recruiting·—·Phase 1·NCT06348108·32 enrolled

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT06896916·135 enrolled

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Active, not recruiting·MMayo Clinic·Phase 1/2·NCT05392946·49 enrolled

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05827016·1,230 enrolled

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT06215118·100 enrolled

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients

Suspended·NNational Cancer Institute (NCI)·Phase 2·NCT06179888·84 enrolled

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (NDMM)

Not yet recruiting·DDana-Farber Cancer Institute·Phase 3·NCT07624513·720 enrolled

A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma

Recruiting· Roche logo

Roche·Preclinical·NCT05583617·200 enrolled

A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial

Recruiting·CCanadian Myeloma Research Group·Phase 2·NCT05272826·75 enrolled

A Randomized Phase III Trial Assessing Iberdomide Versus Iberdomide Plus Isatuximab Maintenance Therapy Post Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Heidelberg Medical Center·Phase 3·NCT06216158·411 enrolled

Feasibility Study of Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Not yet recruiting·SShambavi Richard·Phase 1·NCT07727668·22 enrolled

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06892522·602 enrolled

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·187 enrolled

Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients

Active, not recruiting·SStichting European Myeloma Network·Phase 2·NCT04564703·160 enrolled

A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma

Suspended·HHackensack Meridian Health·Preclinical·NCT05199311·66 enrolled

IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma

Recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT06107738·60 enrolled

Recurrent Multiple Myeloma3 trials

A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06465316·26 enrolled

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

Suspended·AAlliance for Clinical Trials in Oncology·Preclinical·NCT06232044·88 enrolled

Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma

Recruiting·MMayo Clinic·Preclinical·NCT06785415·37 enrolled

Newly Diagnosed Multiple Myeloma2 trials

A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant

Not yet recruiting·DDana-Farber Cancer Institute·Preclinical·NCT07601100·88 enrolled

GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D

Recruiting·PPETHEMA Foundation·Phase 3·NCT05558319·480 enrolled

ESS1 trial

Expanded Access for Iberdomide

Available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07434960

MRD1 trial

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT05434689·80 enrolled

7 more indications

Impairment1 trial

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04933747·26 enrolled

Newly Diagnosed Patients1 trial

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Not yet recruiting·PPETHEMA Foundation·Phase 2·NCT05527340·140 enrolled

Smouldering Myeloma1 trial

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Recruiting·UUniversity College, London·Phase 2·NCT06762769·63 enrolled

Adult1 trial

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05899738·32 enrolled

Dexamethasone1 trial

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Recruiting·—·Phase 1/2·NCT06518551·49 enrolled

Recurrent Ganglioneuroblastoma1 trial

Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy

Not yet recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07437963·76 enrolled

Non-Hodgkin Lymphoma1 trial

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 1·NCT05169515·121 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 13, 2026

ZENBEXUS

NDA NDA221075

Sources

References

[1]
ClinicalTrials.gov — 37 trial records for Iberdomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iberdomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iberdomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA221075). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Modulator[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Related News